Drug Profile
Research programme: T cell therapy - BrightPath Biotherapeutics
Alternative Names: iPS-T; iPS-T(rejT); rejT; T cell therapy - BrightPath BiotherapeuticsLatest Information Update: 14 May 2023
Price :
$50
*
At a glance
- Originator BrightPath Biotherapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Lymphoma
Most Recent Events
- 08 May 2023 Research development is ongoing in Lymphoma in Japan (Parenteral)
- 02 May 2023 BrightPath enters into licensing agreement with Artisan for STAR-CRISPR editing platform to accelerate development of iPSC derived cell therapy platform
- 28 Aug 2021 No recent reports of development identified for research development in Lymphoma in Japan (Parenteral)